Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
ApexOnco Front Page
Recent articles
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
The first global pivotal trial will be in first-line triple-negative breast cancer.
A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
The company scraps nemvaleukin after the latest failure, of Artistry-6.
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
